The Clinical Research Gold Rush
Something unusual is happening in clinical research, and most founders are underestimating it.
On the surface, 2026 looks like a recovery year for biotech and pharma. Beneath that, however, lies a structural reset in how drugs are discovered, developed, and commercialized. Resets like this don't just create growth — they create strategic M&A opportunities that can define the next decade.
If you're a founder or operator of a clinical research site, this is the moment to pay attention.
The Market Isn’t Just Growing, It’s Rewiring Itself
The global contract research organization market is on a significant growth trajectory, projected to expand from around $56.6B in 2025 to over $96B by 2035. What's really happening goes beyond simple supply growth: pharma companies are outsourcing more than ever, trials are becoming increasingly complex in precision medicine and biologics, and CROs are no longer just vendors — they are becoming strategic infrastructure. Infrastructure, historically, tends to consolidate.
For founders of independent, single- or multi-site clinical research businesses, this shift is directly relevant to how buyers are valuing and acquiring sites right now.
M&A Is Back, With Serious Appetite for Founder-Owned Sites
After a cautious 2025, life sciences M&A rebounded strongly. Strategic buyers and private equity-backed platforms aren't just acquiring large CROs — they are actively seeking founder-owned clinical research sites in the lower middle market. These sites offer something larger platforms can't easily replicate: established patient relationships, proven enrollment track records, and deep community roots.
This is creating real demand for well-run sites with $500K to $10M in EBITDA — exactly the businesses that Evergreen M&A was built to serve.
What Buyers are Actually Looking For
The most valuable targets aren't necessarily the largest — they're the most strategically positioned. In today's market, buyers are prioritizing sites with proven operators who have growth potential, embedded physician relationships, strong and reliable patient recruitment, and coverage across multiple therapeutic areas. Sites that have reduced dependence on vaccine studies and have multiple Principal Investigators and Sub-Investigators tend to command stronger interest and higher multiples.
Valuation multiples for well-positioned sites are currently ranging from 4x to 5x EBITDA, with premium assets exceeding that range when the process is run competitively. Anything that de-risks and accelerates clinical development is in demand.
The "Second Bite" Opportunity Most Founders Don't Know About
One of the most compelling — and most overlooked — aspects of selling today is what happens after the initial transaction. Many deals are structured so that founders roll a portion of their proceeds into equity in the acquiring platform. Because these platforms are still in the middle of their own consolidation and growth, that retained equity can double or even triple in value before a second liquidity event occurs.
This means founders who sell now aren't just cashing out — they're positioning themselves for a second and potentially third bite at the apple, at a higher valuation and with far less personal risk than running an independent site.
Why Waiting Could Cost You
Right now, buyers are competing aggressively for high-quality assets. That competition is what drives premium valuations and favorable deal terms. But as consolidation continues, the dynamics will shift: buyers will become more selective, platforms will have already built out their networks, and independent sites will have less negotiating leverage.
Founders who act now benefit from more buyer competition, premium valuations, and better partner selection. Those who wait risk selling into a market where the window for top-tier outcomes has narrowed — or closed.
We've seen this play out directly. A single-site clinical research business in Michigan came to us after receiving offers of $6.1M and $7M. After running a competitive, structured process, we doubled the final enterprise value to $14M — with cash at close 2.3x higher than the prior offer. A similar site in Texas came to us with a $13M offer on the table and closed at $18M.
The difference wasn't the market. It was the process.
What This Means For You As A Founder
Valuation has shifted. It is no longer just about your top line — it's about how your site fits within a rapidly consolidating ecosystem. Private equity platforms are building regional and national footprints, and they are willing to pay a premium for the right assets.
We've seen this firsthand. A single-site clinical research business in Michigan came to us after receiving offers of $6.1M and $7M. After running a competitive, structured process, we doubled the final enterprise value to $14M — with cash at close 2.3x higher than the prior offer. A similar site in Texas came to us with a $13M offer and closed at $18M.
The difference wasn't the market. It was the process.
Timing Matters More Than Founders Realize
Right now, private equity is actively deploying capital, larger platforms are acquiring mid-sized sites, and demand for high-quality assets is increasing. Waiting too long can mean selling into a more competitive or saturated market. Acting during a period of strong demand increases both valuation and deal terms.
The clinical research consolidation wave has already started. The question is whether you're positioned to take advantage of it.
Thinking About Selling?
Whether you're ready to go to market or simply want to understand what your site is worth today, preparation is everything. At Evergreen M&A, we work exclusively with founders of healthcare and clinical research businesses in the lower middle market — guiding them through every stage of the sale process with the strategy, relationships, and execution that deliver premium outcomes.
If you'd like to explore what your clinical research site could be worth in today's market, reach out to Managing Director Hannah Huke at hannah@evergreenforfounders.com.
Contact Us
Our team can help you navigate every part of this journey. At Evergreen M&A, we’ve guided numerous clinical research exits and acquisitions, helping founders and investors capture maximum value in a rapidly consolidating market.
If you’d like to learn more about the current M&A market for clinical research, feel free to reach out to Managing Director, Hannah Huke, at hannah@evergreenforfounders.com.
Contact us today to explore how you can monetize this structural shift.